Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Surveillance

SARS-CoV-2 Prevalence in Malawi Based on Data from Survey of Communities and Health Workers in 5 High-Burden Districts, October 2020

Joe Alex Theu1, Alinune Nathanael Kabaghe1Comments to Author , George Bello, Evelyn Chitsa-Banda, Matthews Kagoli, Andrew Auld, Jonathan Mkungudza, Gabrielle O’Malley, Fred Fredrick Bangara, Elizabeth F. Peacocke, Yusuf Babaye, Wingston Ng’ambi, Christel Saussier, Ellen MacLachlan, Gertrude Chapotera, Mphatso Dennis Phiri, Evelyn Kim, Mabvuto Chiwaula, Danielle Payne, Nellie Wadonda-Kabondo2, Annie Chauma-Mwale2, Titus Henry Divala2, and Public Health Institute of Malawi COVID-19 surveillance committee3
Author affiliations: University of Washington Malawi International Training and Education Center for Health, Lilongwe, Malawi (J.A. Theu, G. Bello, J. Mkungudza, F.F. Bangara, Y. Babaye, C. Saussier); US Centers for Disease Control and Prevention, Malawi, Lilongwe (A.N. Kabaghe, A. Auld, E. Kim, D. Payne, N. Wadonda-Kabondo); Public Health Institute of Malawi, Lilongwe (E. Chitsa-Banda, M. Kagoli, M. Chiwaula, A. Chauma-Mwale); University of Washington International Training and Education Center for Health, Seattle, Washington, USA (G. O’Malley, E. MacLachlan); Norwegian Institute of Public Health, Lilongwe (E.F. Peacocke); Kamuzu University of Health Sciences, Blantyre, Malawi (G. Chapotera, M.D. Phiri, T.H. Divala)

Main Article

Table 3

SARS-CoV-2 signs and symptoms in survey participants with a seropositive test result, Malawi, October 2020

Signs/symptoms of SARS-CoV-2 infection in previous 6 mo Community participants, n = 423
 Health facility staff, n = 124
No.* Weighted % (95% CI) No.* Weighted % (95% CI
None 368 84.7 (78.4–89.4) 107 76.0 (57.9–87.9)
Fever 12 3.5 (1.7–6.8) 6 6.8 (2.6–17.7)
Shortness of breath 2 0.6 (0.11–3.2) 1 1.1 (0.14–7.9)
Sore throat 3 0.8 (0.2–2.7) 4 3.6 (1.2–10.2)
Runny nose 27 9.2 (5.6–14.7) 8 16.6 (5.9–38.5)
Cough 36 10.6 (6.5–16.9) 10 9 (3.7–19.9)
Muscle pain 12 5.2 (2.6–10.0) 3 1.6 (0.5–5.0)
Loss of smell or taste 4 2.3 (0.7–7.6) 4 2.7 (0.9–7.7)
Other signs/symptoms 5 0.7 (0.2–2.2) 3 2.4 (0.7–8.1)
Hospitalization 1 0.7 (0.001–5.0) 0 NA

*Number of participants who reported the symptom among those who tested positive by serology.

Main Article

1These first authors contributed equally to this article.

2These senior authors contributed equally to this article.

3Members are listed at the end of this article.

Page created: July 01, 2022
Page updated: December 11, 2022
Page reviewed: December 11, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external